Mitochondria and Autism Spectrum Disorders

The Neuroscience of Autism Spectrum Disorders

Volumn , Issue , 2013, Pages 179-193

  Naviaux, Robert K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882591036     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-391924-3.00012-0     Document Type: Chapter

References (98)

1. Abbracchio M.P., Burnstock G., Verkhratsky A., Zimmermann H. Purinergic signalling in the nervous system: An overview. Trends In Neurosciences 2009, 32:19-29.
2. Applegarth D.A., Toone J.R., Lowry R.B. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000, 105:e10.
3. Ashwood P., Schauer J., Pessah IN, Van de Water J. Preliminary evidence of the in vitro effects of BDE-47 on innate immune responses in children with Autism spectrum disorders. Journal of Neuroimmunology 2009, 208:130-135.
4. Bernier F.P., Boneh A., Dennett X., Chow C.W., Cleary M.A., Thorburn D.R. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002, 59:1406-1411.
5. Burnstock G., Verkhratsky A. Evolutionary origins of the purinergic signalling system. Acta Physiologica (Oxford) 2009, 195:415-447.
6. Cavalier-Smith T. Origin of mitochondria by intracellular enslavement of a photosynthetic purple bacterium. Proceedings Biological Sciences 2006, 273:1943-1952.
7. Chandrasekaran K., Mehrabian Z., Li X.L., Hassel B. RNase-L regulates the stability of mitochondrial DNA-encoded mRNAs in mouse embryo fibroblasts. Biochemical and Biophysical Research Communications 2004, 325:18-23.
8. Coburn C.G., Curras-Collazo M.C., Kodavanti P.R. In vitro effects of environmentally relevant polybrominated diphenyl ether (PBDE) congeners on calcium buffering mechanisms in rat brain. Neurochemical Research 2008, 33:355-364.
9. Cohen B.H., Naviaux R.K. The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. Methods 2010, 51:364-373.
10. Corcoran J.A., Saffran H.A., Duguay B.A., Smiley J.R. Herpes simplex virus UL12.5 targets mitochondria through a mitochondrial localization sequence proximal to the N terminus. Journal of Virology 2009, 83:2601-2610.
11. Curran L.K., Newschaffer C.J., Lee L.C., Crawford S.O., Johnston M.V., Zimmerman A.W. Behaviors associated with fever in children with Autism spectrum disorders. Pediatrics 2007, 120:e1386-1392.
12. DiMauro S., Bonilla E., Lee C.P., Schotland D.L., Scarpa A., Conn H., et al. Luft's disease: Further biochemical and ultrastructural studies of skeletal muscle in the second case. Journal of the Neurological Sciences 1976, 27:217-232.
13. DiMauro S., Hirano M., Schon E.A. Mitochondrial Medicine. Informa Healthcare 2006.
14. Edmonds J.L., Kirse D.J., Kearns D., Deutsch R., Spruijt L., Naviaux R.K. The otolaryngological manifestations of mitochondrial disease and the risk of neurodegeneration with infection. Archives of Otolaryngology 2002, 128:355-362.
15. Falk M.J. Neurodevelopmental manifestations of mitochondrial disease. Journal of Developmental and Behavioral Pediatrics 2010, 31:610-621.
16. Franke H., Sauer C., Rudolph C., Krugel U., Hengstler J.G., Illes P. P2 receptor-mediated stimulation of the PI3-K/Akt-pathway in vivo. Glia 2009, 57:1031-1045.
17. Frye R.E., Naviaux R.K. Autistic disorder with complex IV overactivity: A new mitochondrial syndrome. Journal of Pediatric Neurology 2011, 9:427-434.
18. Gallego D., Vanden Berghe P., Farre R., Tack J., Jimenez M. P2Y1 receptors mediate inhibitory neuromuscular transmission and enteric neuronal activation in small intestine. Neurogastroenterology and Motility 2008, 20:159-168.
19. Gellerich F.N., Gizatullina Z., Trumbeckaite S., Nguyen H.P., Pallas T., Arandarcikaite O., et al. The regulation of OXPHOS by extramitochondrial calcium. Biochimica et Biophysica Acta 2010, 1797:1018-1027.
20. Gorski C. Dialogue about the potential links between mitochondrial disease and Autism spectrum disorders begins at Indy. UMDF News Release, June 17 2008.
21. Gourine A.V., Dale N., Llaudet E., Poputnikov D.M., Spyer K.M., Gourine V.N. Release of ATP in the central nervous system during systemic inflammation: Real-time measurement in the hypothalamus of conscious rabbits. Journal of Physiology 2007, 585:305-316.
22. Graf W.D., Marin-Garcia J., Gao H.G., Pizzo S., Naviaux R.K., Markusic D., et al. Autism associated with the mitochondrial DNA G8363A transfer RNA(Lys) mutation. Journal of Child Neurology 2000, 15:357-361.
23. Guilmatre A., Dubourg C., Mosca A.L., Legallic S., Goldenberg A., Drouin-Garraud V., et al. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, Autism and mental retardation. Archives of General Psychiatry 2009, 66:947-956.
24. Haas R.H. Autism and mitochondrial disease. Developmental Disabilities Research Reviews 2010, 16:144-153.
25. Haas R.H., Parikh S., Falk M.J., Saneto R.P., Wolf N.I., Darin N., et al. The in-depth evaluation of suspected mitochondrial disease. Molecular Genetics and Metabolism 2008.
26. Hansen R.L., Ozonoff S., Krakowiak P., Angkustsiri K., Jones C., Deprey L.J., et al. Regression in Autism Prevalence and associated factors in the CHARGE Study. Ambulatory Pediatrics 2008, 8:25-31.
27. Helt M., Kelley E., Kinsbourne M., Pandey J., Boorstein H., Herbert M., et al. Can children with Autism recover? If so, how?. Neuropsychology Review 2008, 18:339-366.
28. Hollander E., Chaplin W., Soorya L., Wasserman S., Novotny S., Rusoff J., et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with Autismspectrum disorders. Neuropsychopharmacology 2010, 35:990-998.
29. Holt I.J., Harding A.E., Morgan-Hughes J.A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988, 331:717-719.
30. Housley G.D., Jagger D.J., Greenwood D., Raybould N.P., Salih S.G., Jarlebark L.E., et al. Purinergic regulation of sound transduction and auditory neurotransmission. Audiology and Neurotology 2002, 7:55-61.
31. Jacobson K.A., Boeynaems J.M. P2Y nucleotide receptors: Promise of therapeutic applications. Drug Discovery Today 2010, 15:570-578.
32. James S.J., Cutler P., Melnyk S., Jernigan S., Janak L., Gaylor D.W., et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with Autism. The American Journal of Clinical Nutrition 2004, 80:1611-1617.
33. Jepson B., Granpeesheh D., Tarbox J., Olive M.L., Stott C., Braud S., et al. Controlled evaluation of the effects of hyperbaric oxygen therapy on the behavior of 16 children with Autism spectrum disorders. Journal of Autism and Developmental Disorders 2011, 41:575-588.
34. Ji L.L., Gomez-Cabrera M.C., Vina J. Exercise and hormesis: Activation of cellular antioxidant signaling pathway. Annals of the New York Academy of Sciences 2006, 1067:425-435.
35. Johnson D.T., Harris R.A., Blair P.V., Balaban R.S. Functional consequences of mitochondrial proteome heterogeneity. American Journal of Physiology - Cell Physiology 2007, 292:C698-C707.
36. Jolous-Jamshidi B., Cromwell H.C., McFarland A.M., Meserve L.A. Perinatal exposure to polychlorinated biphenyls alters social behaviors in rats. Toxicology Letters 2010, 199:136-143.
37. Kanner L. Autistic distubances of affective contact. The Nervous Child 1943, 2:217-250.
38. Kauffman M.A., Gonzalez-Moron D., Consalvo D., Westergaard G., Vazquez M., Mancini E., et al. Diagnosis of mitochondrial disorders applying massive pyrosequencing. Molecular Biology Reports 2012.
39. Leng Y., Yamamoto T., Kadowaki M. Alteration of cholinergic, purinergic and sensory neurotransmission in the mouse colon of food allergy model. Neuroscience Letters 2008, 445:195-198.
40. Luft R., Ikkos D., Palmieri G., Ernster L., Afzelius B. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: A correlated clinical, biochemical, and morphological study. Journal of Clinical Investigation 1962, 41:1776-1804.
41. Matos J., Blanco M.G., Maslen S., Skehel J.M., West S.C. Regulatory control of the resolution of DNA recombination intermediates during meiosis and mitosis. Cell 2011, 147:158-172.
42. Matos J.E., Sorensen M.V., Geyti C.S., Robaye B., Boeynaems J.M., Leipziger J. Distal colonic Na(+) absorption inhibited by luminal P2Y(2) receptors. Pflügers Arch 2007, 454:977-987.
43. Mimaki M., Hatakeyama H., Komaki H., Yokoyama M., Arai H., Kirino Y., et al. Reversible infantile respiratory chain deficiency: A clinical and molecular study. Annals of Neurology 2010, 68:845-854.
44. Mouridsen S.E., Bronnum-Hansen H., Rich B., Isager T. Mortality and causes of death in Autism spectrum disorders: An update. Autism 2008, 12:403-414.
45. Munnich A., Rotig A., Chretien D., Cormier V., Bourgeron T., Bonnefont J.P., et al. Clinical presentation of mitochondrial disorders in childhood. Journal of Inherited Metabolic Disease 1996, 19:521-527.
46. Napolioni V., Persico A.M., Porcelli V., Palmieri L. The mitochondrial aspartate/glutamate carrier AGC1 and calcium homeostasis: Physiological links and abnormalities in Autism. Molecular Neurobiology 2011, 44:83-92.
47. Nass M.M., Nass S. Intramitochondrial fibers with DNA characteristics. I. Fixation and electron staining reactions. The Journal of Cell Biology 1963, 19:593-611.
48. Naviaux R.K. The spectrum of mitochondrial disease. Mitochondrial and metabolic disorders: a primary care physcian's guide 1997, 3-10. Psy-Ed Corporation, Oradell, NJ.
49. Naviaux R.K. Developing a systematic approach to the diagnosis and classification of mitochondrial disease. Mitochondrion 2004, 4:351-361.
50. Oliveira G., Ataide A., Marques C., Miguel T.S., Coutinho A.M., Mota-Vieira L., et al. Epidemiology of Autismspectrum disorder in Portugal: Prevalence, clinical characterization, and medical conditions. Developmental Medicine & Child Neurology 2007, 49:726-733.
51. Pagliarini D.J., Calvo S.E., Chang B., Sheth S.A., Vafai S.B., Ong S.E., et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell 2008, 134:112-123.
52. Palmieri L., Papaleo V., Porcelli V., Scarcia P., Gaita L., Sacco R., et al. Altered calcium homeostasis in Autismspectrum disorders: Evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Molecular Archives of General 2010, 15:38-52.
53. Pang T., Cardosa M.J., Guzman M.G. Of cascades and perfect storms: The immunopathogenesis of Dengue haemorrhagic fever-Dengue shock syndrome (DHF/DSS). Immunology & Cell Biology 2007, 85:43-45.
54. Partin J.C. Reye's Syndrome. Liver Disease in Children 1994, 653-671. Mosby, St. Louis, MO. F. Suchy (Ed.).
55. Pastural E., Ritchie S., Lu Y., Jin W., Kavianpour A., Khine Su-Myat K., et al. Novel plasma phospholipid biomarkers of Autism: Mitochondrial dysfunction as a putative causative mechanism. Prostaglandins Leukot Essent Fatty Acids 2009, 81:253-264.
56. Patterson P.H. Immune involvement in schizophrenia and Autism: Etiology, pathology and animal models. Behavioural Brain Research 2009, 204:313-321.
57. Pelegrin P. Targeting interleukin-1 signaling in chronic inflammation: Focus on P2X(7) receptor and Pannexin-1. Drug News Perspect 2008, 21:424-433.
58. Pinto D., Pagnamenta A.T., Klei L., Anney R., Merico D., Regan R., et al. Functional impact of global rare copy number variation in Autism spectrum disorders. Nature 2010, 466:368-372.
59. Poling J.S., Frye R.E., Shoffner J., Zimmerman A.W. Developmental regression and mitochondrial dysfunction in a child with Autism. Journal of Child Neurology 2006, 21:170-172.
60. Rahman S., Blok R.B., Dahl H.H., Danks D.M., Kirby D.M., Chow C.W., et al. Leigh syndrome: Clinical features and biochemical and DNA abnormalities. Annals of Neurology 1996, 39:343-351.
61. Ristow M., Zarse K. How increased oxidative stress promotes longevity and metabolic health: The concept of mitochondrial hormesis (mitohormesis). Experimental Gerontology 2010, 45:410-418.
62. Rossignol D.A., Frye R.E. Mitochondrial dysfunction in Autism spectrum disorders: A systematic review and meta-analysis. Molecular Psychiatry 2011.
63. Rossignol D.A., Rossignol L.W., Smith S., Schneider C., Logerquist S., Usman A., et al. Hyperbaric treatment for children with Autism A multicenter, randomized, double-blind, controlled trial. BMC Pediatrics 2009, 9:21.
64. Rotig A., Lebon S., Zinovieva E., Mollet J., Sarzi E., Bonnefont J.P., et al. Molecular diagnostics of mitochondrial disorders. Biochimica et Biophysica Acta 2004, 1659:129-135.
65. Sadun A.A., La Morgia C., Carelli V. Leber's Hereditary Optic Neuropathy. Current Treatment Options in Neurology 2011, 13:109-117.
66. Saneto R.P., Naviaux R.K. Polymerase gamma disease through the ages. Developmental Disabilities Research Reviews 2010, 16:163-174.
67. Saneto R.P., Lee I.C., Koenig M.K., Bao X., Weng S.W., Naviaux R.K., et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 2010, 19:140-146.
68. Sano M., Fukuda K. Activation of mitochondrial biogenesis by hormesis. Circulation Research 2008, 103:1191-1193.
69. Schaefer A.M., McFarland R., Blakely E.L., He L., Whittaker R.G., Taylor R.W., et al. Prevalence of mitochondrial DNA disease in adults. Annals of Neurology 2008, 63:35-39.
70. Schaeffler A., Gross P., Buettner R., Bollheimer C., Buechler C., Neumeier M., et al. Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology 2009, 126:233-245.
71. Shen P., Wang W., Krishnakumar S., Palm C., Chi A.K., Enns G.M., et al. High-quality DNA sequence capture of 524 disease candidate genes. Proceedings of the National Academy of Sciences USA 2011, 108:6549-6554.
72. Shoffner J., Hyams L., Langley G.N., Cossette S., Mylacraine L., Dale J., et al. Fever plus mitochondrial disease could be risk factors for autistic regression. Journal of Child Neurology 2010, 25:429-434.
73. Singh K.K., Kulawiec M., Still I., Desouki M.M., Geradts J., Matsui S. Inter-genomic cross talk between mitochondria and the nucleus plays an important role in tumorigenesis. Gene 2005, 354:140-146.
74. Staples J.F., Brown J.C. Mitochondrial metabolism in hibernation and daily torpor: A review. Journal of Comparative Physiology B. Biochemical, Systemic, and Environmental Physiology 2008, 178:811-827.
75. Stobbe M. Parents Speak Out on Vaccine Settlement. Washington Post, March 6 2008, Associated Press, Washington, DC.
76. Suliman H.B., Welty-Wolf K.E., Carraway M.S., Schwartz D.A., Hollingsworth J.W., Piantadosi C.A. Toll-like receptor 4 mediates mitochondrial DNA damage and biogenic responses after heat-inactivated E. coli. FASEB Journal 2005, 19:1531-1533.
77. Surprenant A., North R.A. Signaling at purinergic P2X receptors. Annual Review of Physiology 2009, 71:333-359.
78. Trauner D., Sweetman L., Holm J., Kulovich S., Nyhan W.L. Biochemical correlates of illness and recovery in Reye's syndrome. Annals of Neurology 1977, 2:238-241.
79. UMDF United Mitochondrial Disease Foundation (UMDF) Scientific & Medical Advisory Board statement on hyperbaric oxygen Therapy. Mitochondrial News 2007, 12:1-20.
80. Vasta V., Ng S.B., Turner E.H., Shendure J., Hahn S.H. Next generation sequence analysis for mitochondrial disorders. Genome Medicine 2009, 1:100.
81. Verity C.M., Stellitano L.S., Winstone A.M. The PIND study found no association between vaccination and Autismin mitochondrial disease - correction. Developmental Medicine & Child Neurology 2011, 53:477.
82. Verity C.M., Winstone A.M., Stellitano L., Krishnakumar D., Will R., McFarland R. The clinical presentation of mitochondrial diseases in children with progressive intellectual and neurological deterioration: A national, prospective, population-based study. Developmental Medicine & Child Neurology 2010, 52:434-440.
83. Wallace D.C., Singh G., Lott M.T., Hodge J.A., Schurr T.G., Lezza A.M., et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988, 242:1427-1430.
84. Wallace D.C., Zheng X.X., Lott M.T., Shoffner J.M., Hodge J.A., Kelley R.I., et al. Familial mitochondrial encephalomyopathy (MERRF): Genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell 1988, 55:601-610.
85. Wallis C (2008) Case Study: Autismand Vaccines Time Magazine, March 10. Available at: (accessed 24.05.12). http://www.time.com/time/health/article/0%2C%208599%2C%201721109%2C00.ht ml.
86. Weiss M.D., Saneto R.P. Sensory ataxic neuropathy with dysarthria and ophthalmoparesis (SANDO) in late life due to compound heterozygous POLG mutations. Muscle and Nerve 2010, 41:882-885.
87. Weissman J.R., Kelley R.I., Bauman M.L., Cohen B.H., Murray K.F., Mitchell R.L., et al. Mitochondrial disease in Autismspectrum disorder patients: A cohort analysis. PLoS ONE 2008, 3, e3815.
88. West A.P., Shadel G.S., Ghosh S. Mitochondria in innate immune responses. Nature Reviews Immunology 2011, 11:389-402.
89. Wilson J.M. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Molecular Genetics and Metabolism 2009, 96:151-157.
90. Wong L.J. Molecular genetics of mitochondrial disorders. Developmental Disabilities Research Reviews 2010, 16:154-162.
91. Wong L.J., Scaglia F., Graham B.H., Craigen W.J. Current molecular diagnostic algorithm for mitochondrial disorders. Molecular Genetics and Metabolism 2010, 100:111-117.
92. Xu C., Li C.Y., Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Archives of Pharmacal Research 2005, 28:249-268.
93. Yap I.K., Angley M., Veselkov K.A., Holmes E., Lindon J.C., Nicholson J.K. Urinary metabolic phenotyping differentiates children with Autismfrom their unaffected siblings and age-matched controls. Journal of Proteomic Research 2010, 9:2996-3004.
94. Yuen B., Boncompagni S., Feng W., Yang T., Lopez J.R., Matthaei K.I., et al. Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage. FASEB Journal 2012, 26:1311-1322.
95. Zecchini E., Siviero R., Giorgi C., Rizzuto R., Pinton P. Mitochondrial calcium signalling: Message of life and death. The Italian Journal of Biochemistry 2007, 56:235-242.
96. Zeviani M., Moraes C.T., DiMauro S., Nakase H., Bonilla E., Schon E.A., et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988, 38:1339-1346.
97. Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107.
98. Zhao X., Leon I.R., Bak S., Mogensen M., Wrzesinski K., Hojlund K., et al. Phosphoproteome analysis of functional mitochondria isolated from resting human muscle reveals extensive phosphorylation of inner membrane protein complexes and enzymes. Molecular & Cellular Proteomics 2011, 10, M110.000299.